# Royalty Pharma plc (RPRX) FY2025 Annual Balance Sheet

- Company: Royalty Pharma plc (RPRX)
- Period: As of 2025-12-31
- Filing: FY2025 10-K, filed 2026-02-11, accession number 0001802768-26-000003
- Page: https://plicit.ai/financials/rprx/fy2025-annual-balance-sheet
- Chart image: https://plicit.ai/charts/rprx-fy2025-annual-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2025-12-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 19,620,780,000 US dollars
- **Current assets**: 1,528,091,000 US dollars
- **Non-current assets**: 18,092,689,000 US dollars
- **Liabilities**: 9,905,841,000 US dollars
- **Current liabilities**: 636,211,000 US dollars
- **Non-current liabilities**: 9,269,630,000 US dollars
- **Equity**: 9,714,939,000 US dollars
- **Noncontrolling interest**: 3,238,039,000 US dollars. Included in consolidated equity; this amount is not added again.
- **Financial royalty assets**: 854,386,000 US dollars
- **Cash and cash equivalents**: 618,696,000 US dollars
- **Other royalty income receivable**: 29,316,000 US dollars
- **Available for sale debt securities**: 18,800,000 US dollars
- **Other current assets**: 6,893,000 US dollars
- **Financial royalty assets, net**: 16,208,482,000 US dollars
- **Goodwill**: 924,634,000 US dollars
- **Available for sale debt securities**: 419,000,000 US dollars
- **Equity method investments**: 289,968,000 US dollars
- **Equity securities**: 171,312,000 US dollars
- **Other assets**: 79,293,000 US dollars
- **Current portion of long-term debt**: 380,000,000 US dollars
- **Interest payable**: 110,818,000 US dollars
- **Distributions payable to legacy non-controlling interests**: 72,825,000 US dollars
- **Other current liabilities**: 53,164,000 US dollars
- **Accounts payable and accrued expenses**: 19,404,000 US dollars
- **Long-term debt**: 8,570,917,000 US dollars
- **Accrued compensation liabilities**: 577,870,000 US dollars
- **Other liabilities**: 120,843,000 US dollars
- **Additional paid-in capital**: 4,123,088,000 US dollars
- **Retained earnings**: 2,356,318,000 US dollars
- **Common stock - Class R Redeemable Shares**: 63,000 US dollars
- **Common stock - Class A Ordinary Shares**: 43,000 US dollars
- **Deferred shares, $0.000001 par value; issued and outstanding: 2025–411,475 and 2024–392,255**: 0 US dollars
- **Common stock - Class B Ordinary Shares**: 0 US dollars
- **Non-controlling interests**: 3,238,039,000 US dollars
- **Treasury interests**: negative 2,612,000 US dollars
- **Gross equity (calculated)**: 9,717,551,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.